Loading...
Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-Proliferative Agents
Zhao, Huiping Donnelly, Alison C. Kusuma, Bhaskar Reddy Brandt, Gary E. L. Brown, Douglas Rajewski, Roger A. Bielhauer, George Holzbeierlein, Jeffery M. Cohen, Mark S. Blagg, Brian S. J.
Zhao, Huiping
Donnelly, Alison C.
Kusuma, Bhaskar Reddy
Brandt, Gary E. L.
Brown, Douglas
Rajewski, Roger A.
Bielhauer, George
Holzbeierlein, Jeffery M.
Cohen, Mark S.
Blagg, Brian S. J.
Citations
Altmetric:
Abstract
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ~700-fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure–activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest mid-nanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.
Description
Date
2011-06-09
Journal Title
Journal ISSN
Volume Title
Publisher
American Chemical Society
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Zhao, H., Donnelly, A. C., Kusuma, B. R., Brandt, G. E. L., Brown, D., Rajewski, R. A., … Blagg, B. S. J. (2011). Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-Proliferative Agents. Journal of Medicinal Chemistry, 54(11), 3839–3853. http://doi.org/10.1021/jm200148p